Real-World Efficacy and Safety of Anlotinib With and Without Immunotherapy in Advanced Non–Small-Cell Lung Cancer

The aim of this retrospective study is to investigate the efficacy and safety of anlotinib with and without immunotherapy in NSCLC.

Frontiers in Oncology
Correlation Between Early Endpoints and Overall Survival in Non–Small-Cell Lung Cancer

Using multiple source databases, study investigators compile a data set including 81 phase II–IV RCTs of patients with non–small-cell lung cancer.

Frontiers in Oncology
Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer

For patients with resectable stage IIIA NSCLC, neoadjuvant CT with cisplatin and docetaxel followed by surgery resulted in a 1-year EFS rate of 48% in the SAKK 16/00 trial and is an accepted...

Journal of Clinical Oncology

Nivolumab in Non–Small-Cell Lung Cancer: Real World Long-Term Survival Results and Blood-Based Efficacy Biomarkers

Study investigators aim to examine clinical data and baseline blood test results as potential predictive biomarkers for benefit from nivolumab, in advanced non–small-cell lung cancer patients.

Frontiers in Oncology
Development and External Validation of a Nomogram for Predicting Cancer-Specific Survival of Non–Small-Cell Lung Cancer Patients With Ipsilateral Pleural Dissemination

Study investigators aim to build a nomogram to predict lung cancer specific survival of NSCLC patients with ipsilateral pleural dissemination and to compare the impact of primary tumor resection...

Frontiers in Oncology
Prognosis of Stage III Unresectable Mutant Non–Small-Cell Lung Cancer With Tyrosine Kinase Inhibitors Therapy

In a real-world setting, there is room for exploring the benefit of TKIs in stage III unresectable NSCLC patients with mutation.

Frontiers in Oncology
The Effectiveness and Safety of Immune Checkpoint Inhibitors in Non–Small-Cell Lung Cancer Patients With Stage III/IV

This study aims to investigate the effectiveness and safety of ICIs under different treatment conditions of non–small-cell lung cancer patients.

Frontiers in Oncology
Combo Immunotherapy Improves Outcomes for Early-Stage NSCLC

Dr Cascone and colleagues report the findings from their NEOSTAR trial evaluating the clinical activity of neoadjuvant nivolumab monotherapy or nivolumab plus ipilimumab in 44 patients with...

Oncology Times - Latest Articles
Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy

This study seeks to answer the question: can postoperative RT using modern techniques improve survival of patients with pIIIA-N2 NSCLC after complete resection and adjuvant chemotherapy?

JAMA Oncology
Nivolumab with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer

Nivolumab with carboplatin, paclitaxel, and bevacizumab is evaluated as first-line therapy for non-squamous NSCLC.


Annals of Oncology
The Angiotensin-Converting Enzyme Inhibitory State Promotes the Transformation of Non-Small Cell Lung Cancer Blood Supply Pattern Toward Vasculogenic Mimicry Formation

These changes induced by ACE2/ACEI relate to relatively low metastasis rate and comforting prognoses of NSCLC patients.

Frontiers in Oncology
Community Practices Still Not Testing Half of NSCLC Cases

Lung cancer patients treated in community practices are not being comprehensively tested for biomarkers that could guide choice of first-line therapy, a recent retrospective analysis shows.

Inflammatory Markers and Procalcitonin Predict the Outcome of Metastatic Non-Small-Cell-Lung-Cancer Patients Receiving PD-1/PD-L1 Immune-Checkpoint Blockade

This is a retrospective multi-institutional analysis performed on ninety-five mNSCLC patients who received real-world salvage therapy with nivolumab or atezolizumab between December 2015 and April

Frontiers in Oncology
The Anti-Non-Small Cell Lung Cancer Cell Activity by a mTOR Kinase Inhibitor PQR620

In non-small-cell lung carcinoma, aberrant activation of mammalian target of rapamycin contributes to tumorigenesis and cancer progression.

Frontiers in Oncology
ORIENT-12 Study: Addition of Sintilimab to Gemcitabine/Platinum in Advanced Squamous NSCLC

Adding sintilimab to a regimen of gemcitabine and platinum demonstrates clinical benefit over gemcitabine and platinum alone as first-line therapy in patients with locally advanced or metastatic sq

The ASCO Post
ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy

Investigators assess the association between ctDNA metrics and the primary end point of OS in a subset of previously treated patients with locally advanced or metastatic NSCLC, who...

JCO Precision Oncology
Using Liposomes to Alleviate the Toxicity of Chelerythrine, a Natural PKC Inhibitor, in Treating Non-Small Cell Lung Cancer

The present study evaluates the antitumor effect of CHE on non-small cell lung cancer cell line HCC827.

Frontiers in Oncology
Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers

The present study explores changes in pulmonary function, symptoms and radiological signs of pneumonitis after curatively intended stereotactic body radiation therapy.

Frontiers in Oncology
Functional Disability Among Older Versus Younger Adults With Advanced Non–Small-Cell Lung Cancer

This study aims to determine patient and disease characteristics associated with functional disability among adults with advanced non–small-cell lung cancer.

JCO Oncology Practice
Stage IV PD-L1–High Non–Small Cell Lung Cancer: Immunotherapy Alone or With Chemotherapy?

Except in patients with no smoking history, the addition of CT to immunotherapy does not add benefit as a first-line treatment in patients with stage IV nonsquamous NSCLC and high expression of...<

The ASCO Post
Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response in Resectable NSCLC

Neoadjuvant CT with nivolumab plus platinum-doublet chemotherapy significantly improves pathologic complete response rates compared with CT alone in patients with resectable stage IB to IIIA NSCLC.

The ASCO Post
VTE Incidence in NSCLC Varies by Treatment Type

Venous thromboembolism rates among patients with advanced non-small cell lung cancer varied by treatment type, according to retrospective study results.

Superior Survival With Sintilimab in Squamous NSCLC

Second-line treatment with sintilimab improves survival, when compared with docetaxel, in patients with advanced/metastatic squamous non–small cell lung cancer in a phase 3 trial.

GEO Data Mining Identifies OLR1 as a Potential Biomarker in NSCLC Immunotherapy

In this study, investigators attempt to explore TME and identify a potential biomarker for NSCLC immunotherapy.

Frontiers in Oncology
First-Line Immune Checkpoint Inhibitor Monotherapy vs Chemoimmunotherapy in Advanced NSCLC According to KRAS Variant Status

Sun et al find that first-line immune checkpoint inhibitor monotherapy is associated with better OS among patients with advanced NSCLC with PD-L1 expression ≥ 50% and KRAS variant vs KRAS wild-type

The ASCO Post
First-Line Nivolumab/Ipilimumab Plus Chemotherapy Improves Overall Survival vs Chemotherapy in Stage IV or Recurrent NSCLC

This phase III trial has shown improved OS with first-line nivolumab/ipilimumab plus two cycles of CT vs four cycles of CT alone in patients with stage IV or recurrent NSCLC without EGFR o

The ASCO Post
Presurgical Nivo/Chemo Boosts pCR Rates in NSCLC


Results from the CheckMate 816 trial show that pCR rates improved from 2.2% with chemotherapy alone to 24% when nivolumab was added.

Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response Rate for Patients With Resectable NSCLC

Neoadjuvant nivolumab plus platinum-doublet chemotherapy significantly improves pCR rates compared with chemotherapy alone in patients with resectable stage IB to IIIA NSCLC.

The ASCO Post
Final Results From the International Tailored Chemotherapy Adjuvant Trial

Findings from a Phase III study found that evaluating mRNA expression of selected genes to tailor adjuvant chemotherapy did not improve survival outcomes among patients with resected stage II-III N

Oncology Times - Latest Articles
Next Up in NSCLC: Antibody-Drug Conjugates

Antibody-drug conjugates directed against HER2, HER3, and trophoblast cell-surface antigen 2 are showing encouraging antitumor activity in advanced non–small cell lung cancer.

The ASCO Post
Significant Variation Found in Timing & Selection of Genetic Tests for NSCLC

Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however, its use has complicated the diagnosis of non-small cell lung cancer.<

Oncology Times - Latest Articles
Ipilimumab + Pembrolizumab Shows No Benefit for Patients With NSCLC

The addition of ipilimumab to pembrolizumab does not improve efficacy among metastatic NSCLC patients with high levels of PD-L1 expression, according to Phase III findings presented...

Oncology Times - Latest Articles
A Highly Expressed mRNA Signature for Predicting Survival in Patients With Stage I/II Non–Small-Cell Lung Cancer After Operation

This study explores mRNA signature closely related to the prognosis of NSCLC by new algorithm of bioinformatics.

Scientific Reports

source list reference